The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Hexal
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
 
Eudocia Quant Lee
No Relationships to Disclose
 
Alona Muzikansky
No Relationships to Disclose
 
Elizabeth Robins Gerstner
No Relationships to Disclose
 
John G. Kuhn
No Relationships to Disclose
 
David A. Reardon
No Relationships to Disclose
 
Lakshmi Nayak
No Relationships to Disclose
 
Andrew David Norden
No Relationships to Disclose
 
Lisa M. Doherty
No Relationships to Disclose
 
Jennifer Rifenburg
No Relationships to Disclose
 
Debra C. LaFrankie
No Relationships to Disclose
 
Julee Pulverenti
No Relationships to Disclose
 
Trupti Vardam-Kaur
No Relationships to Disclose
 
Deirdre Stokes
No Relationships to Disclose
 
Katrina Howard Smith
No Relationships to Disclose
 
Christine Sceppa McCluskey
No Relationships to Disclose
 
Sarah C. Gaffey
No Relationships to Disclose
 
Tracy Batchelor
Honoraria - Advance Medical; Champions Biotechnology; Educational Concepts Group; Imedex; Oakstone Publishing; Research To Practice; Robert Michael Educational Institute; UpToDate
Consulting or Advisory Role - Agenus; Kirin Pharmaceuticals; Merck; Novartis; Proximagen; Roche/Genentech
Research Funding - AstraZeneca (Inst); Millennium (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Agenus; Kirin Pharmaceuticals; Merck; Novartis; Roche/Genentech
 
Dan G. Duda
No Relationships to Disclose
 
Rakesh K. Jain
Leadership - Tekla Life Sciences; XTuit Pharmaceuticals
Stock and Other Ownership Interests - Enlight Biosciences; Ophthotech; SynDevRx; XTuit Pharmaceuticals
Consulting or Advisory Role - Enlight Biosciences; Noxxon Pharma; Ophthotech; PureTech; SynDevRx
Research Funding - Dyax; MedImmune; Roche Pharma AG
 
Patrick Y. Wen
Consulting or Advisory Role - Abbvie; Cavion; Celldex; Cubist; Genentech/Roche; Midatech Pharma; Momenta Pharmaceuticals; Novartis; Novocure; Sigma-Tau; Vascular Biogenics
Speakers' Bureau - Merck
Research Funding - Agios; Angiochem; AstraZeneca; Exelixis; Genentech/Roche; GlaxoSmithKline; Karyopharm Therapeutics; Novartis; Sanofi; Vascular Biogenics